Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Chinese Medicine
Published in: Chinese Medicine 1/2011

Open Access 01-12-2011 | Review

Anti-cancer natural products isolated from chinese medicinal herbs

Authors: Wen Tan, Jinjian Lu, Mingqing Huang, Yingbo Li, Meiwan Chen, Guosheng Wu, Jian Gong, Zhangfeng Zhong, Zengtao Xu, Yuanye Dang, Jiajie Guo, Xiuping Chen, Yitao Wang

Published in: Chinese Medicine | Issue 1/2011

Login to get access

Abstract

In recent years, a number of natural products isolated from Chinese herbs have been found to inhibit proliferation, induce apoptosis, suppress angiogenesis, retard metastasis and enhance chemotherapy, exhibiting anti-cancer potential both in vitro and in vivo. This article summarizes recent advances in in vitro and in vivo research on the anti-cancer effects and related mechanisms of some promising natural products. These natural products are also reviewed for their therapeutic potentials, including flavonoids (gambogic acid, curcumin, wogonin and silibinin), alkaloids (berberine), terpenes (artemisinin, β-elemene, oridonin, triptolide, and ursolic acid), quinones (shikonin and emodin) and saponins (ginsenoside Rg3), which are isolated from Chinese medicinal herbs. In particular, the discovery of the new use of artemisinin derivatives as excellent anti-cancer drugs is also reviewed.
Appendix
Available only for authorised users
Literature
1.
Bell RM: A review of complementary and alternative medicine practices among cancer survivors. Clin J Oncol Nurs. 2010, 14: 365-370. 10.1188/10.CJON.365-370.PubMed
2.
Newman DJ, Cragg GM, Snader KM: Natural products as sources of new drugs over the period 1981-2002. J Nat Prod. 2003, 66: 1022-1037. 10.1021/np030096l.PubMed
3.
Panthong A, Norkaew P, Kanjanapothi D, Taesotikul T, Anantachoke N, Reutrakul V: Anti-inflammatory, analgesic and antipyretic activities of the extract of gamboge from Garcinia hanburyi Hook f. J Ethnopharmacol. 2007, 111: 335-340. 10.1016/j.jep.2006.11.038.PubMed
4.
Kasibhatla S, Jessen KA, Maliartchouk S, Wang JY, English NM, Drewe J, Qiu L, Archer SP, Ponce AE, Sirisoma N, Jiang S, Zhang HZ, Gehlsen KR, Cai SX, Green DR, Tseng B: A role for transferrin receptor in triggering apoptosis when targeted with gambogic acid. Proc Natl Acad Sci USA. 2005, 102: 12095-12100. 10.1073/pnas.0406731102.PubMedCentralPubMed
5.
Gu H, Wang X, Rao S, Wang J, Zhao J, Ren FL, Mu R, Yang Y, Qi Q, Liu W, Lu N, Ling H, You Q, Guo Q: Gambogic acid mediates apoptosis as a p53 inducer through down-regulation of mdm2 in wild-type p53-expressing cancer cells. Mol Cancer Ther. 2008, 7: 3298-3305. 10.1158/1535-7163.MCT-08-0212.PubMed
6.
Wu ZQ, Guo QL, You QD, Zhao L, Gu HY: Gambogic acid inhibits proliferation of human lung carcinoma SPC-A1 cells in vivo and in vitro and represses telomerase activity and telomerase reverse transcriptase mRNA expression in the cells. Biol Pharm Bull. 2004, 27: 1769-1774. 10.1248/bpb.27.1769.PubMed
7.
Qiang L, Yang Y, You QD, Ma YJ, Yang L, Nie FF, Gu HY, Zhao L, Lu N, Qi Q, Liu W, Wang XT, Guo QL: Inhibition of glioblastoma growth and angiogenesis by gambogic acid: an in vitro and in vivo study. Biochem Pharmacol. 2008, 75: 1083-1092. 10.1016/j.bcp.2007.10.033.PubMed
8.
Qi Q, Gu H, Yang Y, Lu N, Zhao J, Liu W, Ling H, You QD, Wang X, Guo Q: Involvement of matrix metalloproteinase 2 and 9 in gambogic acid induced suppression of MDA-MB-435 human breast carcinoma cell lung metastasis. J Mol Med. 2008, 86: 1367-1377. 10.1007/s00109-008-0398-z.PubMed
9.
Wang X, Chen Y, Han QB, Chan CY, Wang H, Liu Z, Cheng CH, Yew DT, Lin MC, He ML, Xu HX, Sung JJ, Kung HF: Proteomic identification of molecular targets of gambogic acid: role of stathmin in hepatocellular carcinoma. Proteomics. 2009, 9: 242-253. 10.1002/pmic.200800155.PubMed
10.
Rong JJ, Hu R, Qi Q, Gu HY, Zhao Q, Wang J, Mu R, You QD, Guo QL: Gambogic acid down-regulates MDM2 oncogene and induces p21(Waf1/CIP1) expression independent of p53. Cancer Lett. 2009, 284: 102-112. 10.1016/j.canlet.2009.04.011.PubMed
11.
Zhai D, Jin C, Shiau CW, Kitada S, Satterthwait AC, Reed JC: Gambogic acid is an antagonist of antiapoptotic Bcl-2 family proteins. Mol Cancer Ther. 2008, 7: 1639-1646. 10.1158/1535-7163.MCT-07-2373.PubMedCentralPubMed
12.
Pandey MK, Sung B, Ahn KS, Kunnumakkara AB, Chaturvedi MM, Aggarwal BB: Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-kappaB signaling pathway. Blood. 2007, 110: 3517-3525. 10.1182/blood-2007-03-079616.PubMedCentralPubMed
13.
Qin Y, Meng L, Hu C, Duan W, Zuo Z, Lin L, Zhang X, Ding J: Gambogic acid inhibits the catalytic activity of human topoisomerase IIalpha by binding to its ATPase domain. Mol Cancer Ther. 2007, 6: 2429-2440. 10.1158/1535-7163.MCT-07-0147.PubMed
14.
Zhao J, Qi Q, Yang Y, Gu HY, Lu N, Liu W, Wang W, Qiang L, Zhang LB, You QD, Guo QL: Inhibition of alpha(4) integrin mediated adhesion was involved in the reduction of B16-F10 melanoma cells lung colonization in C57BL/6 mice treated with gambogic acid. Eur J Pharmacol. 2008, 589: 127-131. 10.1016/j.ejphar.2008.04.063.PubMed
15.
He D, Xu Q, Yan M, Zhang P, Zhou X, Zhang Z, Duan W, Zhong L, Ye D, Chen W: The NF-kappa B inhibitor, celastrol, could enhance the anti-cancer effect of gambogic acid on oral squamous cell carcinoma. BMC Cancer. 2009, 9: 343-10.1186/1471-2407-9-343.PubMedCentralPubMed
16.
Wang J, Liu W, Zhao Q, Qi Q, Lu N, Yang Y, Nei FF, Rong JJ, You QD, Guo QL: Synergistic effect of 5-fluorouracil with gambogic acid on BGC-823 human gastric carcinoma. Toxicology. 2009, 256: 135-140. 10.1016/j.tox.2008.11.014.PubMed
17.
Wang T, Wei J, Qian X, Ding Y, Yu L, Liu B: Gambogic acid, a potent inhibitor of survivin, reverses docetaxel resistance in gastric cancer cells. Cancer Lett. 2008, 262: 214-222. 10.1016/j.canlet.2007.12.004.PubMed
18.
Chen B, Liang Y, Wu W, Cheng J, Xia G, Gao F, Ding J, Gao C, Shao Z, Li G, Chen W, Xu W, Sun X, Liu L, Li X, Wang X: Synergistic effect of magnetic nanoparticles of Fe(3)O(4) with gambogic acid on apoptosis of K562 leukemia cells. Int J Nanomedicine. 2009, 4: 251-259.PubMedCentralPubMed
19.
Minami M, Nishio K, Ajioka Y, Kyushima H, Shigeki K, Kinjo K, Yamada K, Nagai M, Satoh K, Sakurai Y: Identification of Curcuma plants and curcumin content level by DNA polymorphisms in the trnS-trnfM intergenic spacer in chloroplast DNA. J Nat Med. 2009, 63: 75-79. 10.1007/s11418-008-0283-7.PubMed
20.
Goel A, Kunnumakkara AB, Aggarwal BB: Curcumin as "Curecumin": from kitchen to clinic. Biochem Pharmacol. 2008, 75: 787-809. 10.1016/j.bcp.2007.08.016.PubMed
21.
Lopez-Lazaro M: Anticancer and carcinogenic properties of curcumin: considerations for its clinical development as a cancer chemopreventive and chemotherapeutic agent. Mol Nutr Food Res. 2008, 52 (Suppl 1): S103-127.PubMed
22.
Bhandarkar SS, Arbiser JL: Curcumin as an inhibitor of angiogenesis. Adv Exp Med Biol. 2007, 595: 185-195. 10.1007/978-0-387-46401-5_7.PubMed
23.
Ravindran J, Prasad S, Aggarwal BB: Curcumin and cancer cells: how many ways can curry kill tumor cells selectively?. AAPS J. 2009, 11: 495-510. 10.1208/s12248-009-9128-x.PubMedCentralPubMed
24.
Aggarwal BB, Shishodia S, Takada Y, Banerjee S, Newman RA, Bueso-Ramos CE, Price JE: Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res. 2005, 11: 7490-7498. 10.1158/1078-0432.CCR-05-1192.PubMed
25.
Binion DG, Otterson MF, Rafiee P: Curcumin inhibits VEGF-mediated angiogenesis in human intestinal microvascular endothelial cells through COX-2 and MAPK inhibition. Gut. 2008, 57: 1509-1517. 10.1136/gut.2008.152496.PubMedCentralPubMed
26.
Shinojima N, Yokoyama T, Kondo Y, Kondo S: Roles of the Akt/mTOR/p70S6K and ERK1/2 signaling pathways in curcumin- induced autophagy. Autophagy. 2007, 3: 635-637.PubMed
27.
Aoki H, Takada Y, Kondo S, Sawaya R, Aggarwal BB, Kondo Y: Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: role of Akt and extracellular signal-regulated kinase signaling pathways. Mol Pharmacol. 2007, 72: 29-39. 10.1124/mol.106.033167.PubMed
28.
Jia YL, Li J, Qin ZH, Liang ZQ: Autophagic and apoptotic mechanisms of curcumin-induced death in K562 cells. J Asian Nat Prod Res. 2009, 11: 918-928. 10.1080/10286020903264077.PubMed
29.
Yoon MJ, Kim EH, Lim JH, Kwon TK, Choi KS: Superoxide anion and proteasomal dysfunction contribute to curcumin-induced paraptosis of malignant breast cancer cells. Free Radic Biol Med. 2009, 48: 713-726.PubMed
30.
Nautiyal J, Banerjee S, Kanwar SS, Yu Y, Patel BB, Sarkar FH, Majumdar AP: Curcumin enhances dasatinib-induced inhibition of growth and transformation of colon cancer cells. Int J Cancer. 2011, 128: 951-961. 10.1002/ijc.25410.PubMedCentralPubMed
31.
Ibrahim MA, Elbehairy AM, Ghoneim MA, Amer HA: Protective effect of curcumin and chlorophyllin against DNA mutation induced by cyclophosphamide or benzo[a]pyrene. Z Naturforsch C. 2007, 62: 215-222.PubMed
32.
Arafa HM: Uroprotective effects of curcumin in cyclophosphamide -induced haemorrhagic cystitis paradigm. Basic Clin Pharmacol Toxicol. 2009, 104: 393-399. 10.1111/j.1742-7843.2009.00379.x.PubMed
33.
Venkatesan N, Chandrakasan G: Modulation of cyclophosphamide-induced early lung injury by curcumin, an anti-inflammatory antioxidant. Mol Cell Biochem. 1995, 142: 79-87. 10.1007/BF00928916.PubMed
34.
Siddique YH, Ara G, Beg T, Gupta J, Afzal M: Assessment of cell viability, lipid peroxidation and quantification of DNA fragmentation after the treatment of anticancerous drug mitomycin C and curcumin in cultured human blood lymphocytes. Exp Toxicol Pathol. 2010, 62: 503-508. 10.1016/j.etp.2009.06.010.PubMed
35.
Zhou QM, Zhang H, Lu YY, Wang XF, Su SB: Curcumin reduced the side effects of mitomycin C by inhibiting GRP58-mediated DNA cross-linking in MCF-7 breast cancer xenografts. Cancer Sci. 2009, 100: 2040-2045. 10.1111/j.1349-7006.2009.01297.x.PubMed
36.
Howells LM, Sale S, Sriramareddy SN, Irving GR, Jones DJ, Ottley CJ, Pearson DG, Mann CD, Manson MM, Berry DP, Gescher A, Steward WP, Brown K: Curcumin ameliorates oxaliplatin-induced chemoresistance in HCT116 colorectal cancer cells in vitro and in vivo. Int J Cancer. 2010,
37.
Goel A, Aggarwal BB: Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr Cancer. 2010, 62: 919-930. 10.1080/01635581.2010.509835.PubMed
38.
Yallapu MM, Maher DM, Sundram V, Bell MC, Jaggi M, Chauhan SC: Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth. J Ovarian Res. 2010, 3: 11-10.1186/1757-2215-3-11.PubMedCentralPubMed
39.
Hatcher H, Planalp R, Cho J, Torti FM, Torti SV: Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci. 2008, 65: 1631-1652. 10.1007/s00018-008-7452-4.PubMed
40.
Bayet-Robert M, Kwiatkowski F, Leheurteur M, Gachon F, Planchat E, Abrial C, Mouret-Reynier MA, Durando X, Barthomeuf C, Chollet P: Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer. Cancer Biol Ther. 2009, 9: 8-14.
41.
Kanai M, Yoshimura K, Asada M, Imaizumi A, Suzuki C, Matsumoto S, Nishimura T, Mori Y, Masui T, Kawaguchi Y, Yanagihara K, Yazumi S, Chiba T, Guha S, Aggarwal BB: A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Cancer Chemother Pharmacol. 2011, 68: 157-164. 10.1007/s00280-010-1470-2.PubMed
42.
Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, Ng CS, Badmaev V, Kurzrock R: Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res. 2008, 14: 4491-4499. 10.1158/1078-0432.CCR-08-0024.PubMed
43.
Li C, Zhou L, Lin G, Zuo Z: Contents of major bioactive flavones in proprietary traditional Chinese medicine products and reference herb of radix Scutellariae. J Pharm Biomed Anal. 2009, 50: 298-306. 10.1016/j.jpba.2009.04.028.PubMed
44.
Baumann S, Fas SC, Giaisi M, Müller WW, Merling A, Gülow K, Edler L, Krammer PH, Li-Weber M: Wogonin preferentially kills malignant lymphocytes and suppresses T-cell tumor growth by inducing PLCγ1- and Ca2+ -dependent apoptosis. Blood. 2008, 111: 2354-2363. 10.1182/blood-2007-06-096198.PubMed
45.
Yu JQ, Liu HB, Tian DZ, Liu YW, Lei JC, Zou GL: Changes in mitochondrial membrane potential and reactive oxygen species during wogonin-induced cell death in human hepatoma cells. Hepatol Res. 2007, 37: 68-76. 10.1111/j.1872-034X.2007.00003.x.PubMed
46.
Himeji M, Ohtsuki T, Fukazawa H, Tanaka M, Yazaki S-i, Ui S, Nishio K, Yamamoto H, Tasaka K, Mimura A: Difference of growth-inhibitory effect of Scutellaria baicalensis-producing flavonoid wogonin among human cancer cells and normal diploid cell. Cancer Lett. 2007, 245: 269-274. 10.1016/j.canlet.2006.01.011.PubMed
47.
Lee D-H, Kim C, Zhang L, Lee YJ: Role of p53, PUMA, and Bax in wogonin-induced apoptosis in human cancer cells. Biochem Pharmacol. 2008, 75: 2020-2033. 10.1016/j.bcp.2008.02.023.PubMedCentralPubMed
48.
Yang L, Zhang HW, Hu R, Yang Y, Qi Q, Lu N, Liu W, Chu YY, You QD, Guo QL: Wogonin induces G1 phase arrest through inhibiting Cdk4 and cyclin D1 concomitant with an elevation in p21Cip1 in human cervical carcinoma HeLa cells. Biochem Cell Biol. 2009, 87: 933-942. 10.1139/O09-060.PubMed
49.
Lu N, Gao Y, Ling Y, Chen Y, Yang Y, Gu H-Y, Qi Q, Liu W, Wang X-T, You Q-D, Guo Q-L: Wogonin suppresses tumor growth in vivo and VEGF-induced angiogenesis through inhibiting tyrosine phosphorylation of VEGFR2. Life Sci. 2008, 82: 956-963. 10.1016/j.lfs.2008.02.013.PubMed
50.
Lee E, Enomoto R, Koshiba C, Hirano H: Inhibition of P-glycoprotein by wogonin is involved with the potentiation of etoposide-induced apoptosis in cancer cells. Ann N Y Acad Sci. 2009, 1171: 132-136. 10.1111/j.1749-6632.2009.04722.x.PubMed
51.
Lee E, Enomoto R, Suzuki C, Ohno M, Ohashi T, Miyauchi A, Tanimoto E, Maeda K, Hirano H, Yokoi T, Sugahara C: Wogonin, a plant flavone, potentiates etoposide-induced apoptosis in cancer cells. Ann N Y Acad Sci. 2007, 1095: 521-526. 10.1196/annals.1397.056.PubMed
52.
Enomoto R, Koshiba C, Suzuki C, Lee E: Wogonin potentiates the antitumor action of etoposide and ameliorates its adverse effects. Cancer Chemother Pharmacol. 2011, 67: 1063-1072. 10.1007/s00280-010-1396-8.PubMed
53.
Zhao Q, Wang J, Zou MJ, Hu R, Zhao L, Qiang L, Rong JJ, You QD, Guo QL: Wogonin potentiates the antitumor effects of low dose 5-fluorouracil against gastric cancer through induction of apoptosis by down-regulation of NF-kappaB and regulation of its metabolism. Toxicol Lett. 2010, 197: 201-210. 10.1016/j.toxlet.2010.05.019.PubMed
54.
Li-Weber M: New therapeutic aspects of flavones: The anticancer properties of Scutellaria and its main active constituents Wogonin, Baicalein and Baicalin. Cancer Treatment Reviews. 2009, 35: 57-68. 10.1016/j.ctrv.2008.09.005.PubMed
55.
Rajamanickam S, Velmurugan B, Kaur M, Singh RP, Agarwal R: Chemoprevention of intestinal tumorigenesis in APCmin/+ mice by silibinin. Cancer Res. 2010, 70: 2368-2378. 10.1158/0008-5472.CAN-09-3249.PubMedCentralPubMed
56.
Singh RP, Raina K, Deep G, Chan D, Agarwal R: Silibinin suppresses growth of human prostate carcinoma PC-3 orthotopic xenograft via activation of extracellular signal-regulated kinase 1/2 and inhibition of signal transducers and activators of transcription signaling. Clin Cancer Res. 2009, 15: 613-621. 10.1158/1078-0432.CCR-08-1846.PubMedCentralPubMed
57.
Singh RP, Raina K, Sharma G, Agarwal R: Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice. Clin Cancer Res. 2008, 14: 7773-7780. 10.1158/1078-0432.CCR-08-1309.PubMedCentralPubMed
58.
Tiwari P, Kumar A, Balakrishnan S, Kushwaha HS, Mishra KP: Silibinin-induced apoptosis in MCF7 and T47D human breast carcinoma cells involves caspase-8 activation and mitochondrial pathway. Cancer Invest. 2011, 29: 12-20. 10.3109/07357907.2010.535053.PubMed
59.
Cui W, Gu F, Hu KQ: Effects and mechanisms of silibinin on human hepatocellular carcinoma xenografts in nude mice. World J Gastroenterol. 2009, 15: 1943-1950. 10.3748/wjg.15.1943.PubMedCentralPubMed
60.
Raina K, Rajamanickam S, Singh RP, Deep G, Chittezhath M, Agarwal R: Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model. Cancer Res. 2008, 68: 6822-6830. 10.1158/0008-5472.CAN-08-1332.PubMedCentralPubMed
61.
Mateen S, Tyagi A, Agarwal C, Singh RP, Agarwal R: Silibinin inhibits human nonsmall cell lung cancer cell growth through cell-cycle arrest by modulating expression and function of key cell-cycle regulators. Mol Carcinog. 2010, 49: 247-258.PubMedCentralPubMed
62.
Li L, Zeng J, Gao Y, He D: Targeting silibinin in the antiproliferative pathway. Expert Opin Investig Drugs. 2010, 19: 243-255. 10.1517/13543780903533631.PubMed
63.
Agarwal C, Tyagi A, Kaur M, Agarwal R: Silibinin inhibits constitutive activation of Stat3, and causes caspase activation and apoptotic death of human prostate carcinoma DU145 cells. Carcinogenesis. 2007, 28: 1463-1470. 10.1093/carcin/bgm042.PubMed
64.
Wang X, Gocek E, Novik V, Harrison JS, Danilenko M, Studzinski GP: Inhibition of Cot1/Tlp2 oncogene in AML cells reduces ERK5 activation and up-regulates p27Kip1 concomitant with enhancement of differentiation and cell cycle arrest induced by silibinin and 1,25-dihydroxyvitamin D(3). Cell Cycle. 2010, 9: 4542-4551.PubMedCentralPubMed
65.
Ong ES, Woo SO, Yong YL: Pressurized liquid extraction of berberine and aristolochic acids in medicinal plants. J Chromatogr A. 2000, 904: 57-64. 10.1016/S0021-9673(00)00914-6.PubMed
66.
Lee IA, Hyun YJ, Kim DH: Berberine ameliorates TNBS-induced colitis by inhibiting lipid peroxidation, enterobacterial growth and NF-kappaB activation. Eur J Pharmacol. 2010, 648: 162-170. 10.1016/j.ejphar.2010.08.046.PubMed
67.
Liu X, Li G, Zhu H, Huang L, Liu Y, Ma C, Qin C: Beneficial effect of berberine on hepatic insulin resistance in diabetic hamsters possibly involves in SREBPs, LXRalpha and PPARalpha transcriptional programs. Endocr J. 2010, 57: 881-893. 10.1507/endocrj.K10E-043.PubMed
68.
Zhou J, Zhou S: Berberine regulates peroxisome proliferator-activated receptors and positive transcription elongation factor b expression in diabetic adipocytes. Eur J Pharmacol. 2010, 649: 390-397. 10.1016/j.ejphar.2010.09.030.PubMed
69.
Wu M, Wang J, Liu LT: Advance of studies on anti-atherosclerosis mechanism of berberine. Chin J Integr Med. 2010, 16: 188-192. 10.1007/s11655-010-0188-7.PubMed
70.
Zhao L, Li W, Han F, Hou L, Baillargeon JP, Kuang H, Wang Y, Wu X: Berberine reduces insulin resistance induced by dexamethasone in theca cells in vitro. Fertil Steril. 2011, 95: 461-463. 10.1016/j.fertnstert.2010.07.1090.PubMed
71.
Remppis A, Bea F, Greten HJ, Buttler A, Wang H, Zhou Q, Preusch MR, Enk R, Ehehalt R, Katus H, Blessing E: Rhizoma Coptidis inhibits LPS-induced MCP-1/CCL2 production in murine macrophages via an AP-1 and NFkappaB-dependent pathway. Mediators Inflamm. 2010, 2010: 194896-PubMedCentralPubMed
72.
Choi MS, Yuk DY, Oh JH, Jung HY, Han SB, Moon DC, Hong JT: Berberine inhibits human neuroblastoma cell growth through induction of p53-dependent apoptosis. Anticancer Res. 2008, 28: 3777-3784.PubMed
73.
Ho YT, Lu CC, Yang JS, Chiang JH, Li TC, Ip SW, Hsia TC, Liao CL, Lin JG, Wood WG, Chung JG: Berberine induced apoptosis via promoting the expression of caspase-8, -9 and -3, apoptosis-inducing factor and endonuclease G in SCC-4 human tongue squamous carcinoma cancer cells. Anticancer Res. 2009, 29: 4063-4070.PubMed
74.
Hsu WH, Hsieh YS, Kuo HC, Teng CY, Huang HI, Wang CJ, Yang SF, Liou YS, Kuo WH: Berberine induces apoptosis in SW620 human colonic carcinoma cells through generation of reactive oxygen species and activation of JNK/p38 MAPK and FasL. Arch Toxicol. 2007, 81: 719-728. 10.1007/s00204-006-0169-y.PubMed
75.
James MA, Fu H, Liu Y, Chen DR, You M: Dietary administration of berberine or Phellodendron amurense extract inhibits cell cycle progression and lung tumorigenesis. Mol Carcinog. 2011, 50: 1-7. 10.1002/mc.20690.PubMed
76.
Patil JB, Kim J, Jayaprakasha GK: Berberine induces apoptosis in breast cancer cells (MCF-7) through mitochondrial-dependent pathway. Eur J Pharmacol. 2010, 645: 70-78. 10.1016/j.ejphar.2010.07.037.PubMed
77.
Auyeung KK, Ko JK: Coptis chinensis inhibits hepatocellular carcinoma cell growth through nonsteroidal anti-inflammatory drug-activated gene activation. Int J Mol Med. 2009, 24: 571-577.PubMed
78.
Yu FS, Yang JS, Lin HJ, Yu CS, Tan TW, Lin YT, Lin CC, Lu HF, Chung JG: Berberine inhibits WEHI-3 leukemia cells in vivo. In Vivo. 2007, 21: 407-412.PubMed
79.
Meeran SM, Katiyar S, Katiyar SK: Berberine-induced apoptosis in human prostate cancer cells is initiated by reactive oxygen species generation. Toxicol Appl Pharmacol. 2008, 229: 33-43. 10.1016/j.taap.2007.12.027.PubMed
80.
Pandey MK, Sung B, Kunnumakkara AB, Sethi G, Chaturvedi MM, Aggarwal BB: Berberine modifies cysteine 179 of IkappaBalpha kinase, suppresses nuclear factor-kappaB-regulated antiapoptotic gene products, and potentiates apoptosis. Cancer Res. 2008, 68: 5370-5379. 10.1158/0008-5472.CAN-08-0511.PubMed
81.
Qin Y, Pang JY, Chen WH, Zhao ZZ, Liu L, Jiang ZH: Inhibition of DNA topoisomerase I by natural and synthetic mono- and dimeric protoberberine alkaloids. Chem Biodivers. 2007, 4: 481-487. 10.1002/cbdv.200790040.PubMed
82.
Katiyar SK, Meeran SM, Katiyar N, Akhtar S: p53 Cooperates berberine-induced growth inhibition and apoptosis of non-small cell human lung cancer cells in vitro and tumor xenograft growth in vivo. Mol Carcinog. 2009, 48: 24-37. 10.1002/mc.20453.PubMed
83.
Maiti M, Kumar GS: Polymorphic nucleic Acid binding of bioactive isoquinoline alkaloids and their role in cancer. J Nucleic Acids. 2010, 2010:
84.
Bhadra K, Kumar GS: Therapeutic potential of nucleic acid-binding isoquinoline alkaloids: Binding aspects and implications for drug design. Med Res Rev. 2010,
85.
Tian X, Song Y, Dong H, Ye B: Interaction of anticancer herbal drug berberine with DNA immobilized on the glassy carbon electrode. Bioelectrochemistry. 2008, 73: 18-22. 10.1016/j.bioelechem.2008.02.005.PubMed
86.
Serafim TL, Oliveira PJ, Sardao VA, Perkins E, Parke D, Holy J: Different concentrations of berberine result in distinct cellular localization patterns and cell cycle effects in a melanoma cell line. Cancer Chemother Pharmacol. 2008, 61: 1007-1018. 10.1007/s00280-007-0558-9.PubMed
87.
Kim JB, Yu JH, Ko E, Lee KW, Song AK, Park SY, Shin I, Han W, Noh DY: The alkaloid Berberine inhibits the growth of Anoikis-resistant MCF-7 and MDA-MB-231 breast cancer cell lines by inducing cell cycle arrest. Phytomedicine. 2010, 17: 436-440. 10.1016/j.phymed.2009.08.012.PubMed
88.
Eom KS, Hong JM, Youn MJ, So HS, Park R, Kim JM, Kim TY: Berberine induces G1 arrest and apoptosis in human glioblastoma T98G cells through mitochondrial/caspases pathway. Biol Pharm Bull. 2008, 31: 558-562. 10.1248/bpb.31.558.PubMed
89.
Pereira CV, Machado NG, Oliveira PJ: Mechanisms of berberine (natural yellow 18)-induced mitochondrial dysfunction: interaction with the adenine nucleotide translocator. Toxicol Sci. 2008, 105: 408-417. 10.1093/toxsci/kfn131.PubMed
90.
Wang N, Feng Y, Zhu M, Tsang CM, Man K, Tong Y, Tsao SW: Berberine induces autophagic cell death and mitochondrial apoptosis in liver cancer cells: the cellular mechanism. J Cell Biochem. 2010, 111: 1426-1436. 10.1002/jcb.22869.PubMed
91.
Peng PL, Kuo WH, Tseng HC, Chou FP: Synergistic tumor-killing effect of radiation and berberine combined treatment in lung cancer: the contribution of autophagic cell death. Int J Radiat Oncol Biol Phys. 2008, 70: 529-542. 10.1016/j.ijrobp.2007.08.034.PubMed
92.
Singh T, Vaid M, Katiyar N, Sharma S, Katiyar SK: Berberine, an isoquinoline alkaloid, inhibits melanoma cancer cell migration by reducing the expressions of cyclooxygenase-2, prostaglandin E and prostaglandin E receptors. Carcinogenesis. 2011, 32: 86-92. 10.1093/carcin/bgq215.PubMedCentralPubMed
93.
Tsang CM, Lau EP, Di K, Cheung PY, Hau PM, Ching YP, Wong YC, Cheung AL, Wan TS, Tong Y, Tsao SW, Feng Y: Berberine inhibits Rho GTPases and cell migration at low doses but induces G2 arrest and apoptosis at high doses in human cancer cells. Int J Mol Med. 2009, 24: 131-138.PubMed
94.
Tang F, Wang D, Duan C, Huang D, Wu Y, Chen Y, Wang W, Xie C, Meng J, Wang L, Wu B, Liu S, Tian D, Zhu F, He Z, Deng F, Cao Y: Berberine inhibits metastasis of nasopharyngeal carcinoma 5-8F cells by targeting Rho kinase-mediated Ezrin phosphorylation at threonine 567. J Biol Chem. 2009, 284: 27456-27466. 10.1074/jbc.M109.033795.PubMedCentralPubMed
95.
Lin TH, Kuo HC, Chou FP, Lu FJ: Berberine enhances inhibition of glioma tumor cell migration and invasiveness mediated by arsenic trioxide. BMC Cancer. 2008, 8: 58-10.1186/1471-2407-8-58.PubMedCentralPubMed
96.
Kim DW, Ahan SH, Kim TY: Enhancement of Arsenic Trioxide (As(2)O(3))- Mediated Apoptosis Using Berberine in Human Neuroblastoma SH-SY5Y Cells. J Korean Neurosurg Soc. 2007, 42: 392-399. 10.3340/jkns.2007.42.5.392.PubMedCentralPubMed
97.
Youn MJ, So HS, Cho HJ, Kim HJ, Kim Y, Lee JH, Sohn JS, Kim YK, Chung SY, Park R: Berberine, a natural product, combined with cisplatin enhanced apoptosis through a mitochondria/caspase-mediated pathway in HeLa cells. Biol Pharm Bull. 2008, 31: 789-795. 10.1248/bpb.31.789.PubMed
98.
Hur JM, Hyun MS, Lim SY, Lee WY, Kim D: The combination of berberine and irradiation enhances anti-cancer effects via activation of p38 MAPK pathway and ROS generation in human hepatoma cells. J Cell Biochem. 2009, 107: 955-964. 10.1002/jcb.22198.PubMed
99.
Zhang X, Gu L, Li J, Shah N, He J, Yang L, Hu Q, Zhou M: Degradation of MDM2 by the interaction between berberine and DAXX leads to potent apoptosis in MDM2-overexpressing cancer cells. Cancer Res. 2010, 70: 9895-9904. 10.1158/0008-5472.CAN-10-1546.PubMedCentralPubMed
100.
Gui SY, Wu L, Peng DY, Liu QY, Yin BP, Shen JZ: Preparation and evaluation of a microemulsion for oral delivery of berberine. Pharmazie. 2008, 63: 516-519.PubMed
101.
Cheng Z, Chen AF, Wu F, Sheng L, Zhang HK, Gu M, Li YY, Zhang LN, Hu LH, Li JY, Li J: 8,8-Dimethyldihydroberberine with improved bioavailability and oral efficacy on obese and diabetic mouse models. Bioorg Med Chem. 2010, 18: 5915-5924. 10.1016/j.bmc.2010.06.085.PubMed
102.
Pan GY, Wang GJ, Liu XD, Fawcett JP, Xie YY: The involvement of P-glycoprotein in berberine absorption. Pharmacol Toxicol. 2002, 91: 193-197. 10.1034/j.1600-0773.2002.t01-1-910403.x.PubMed
103.
Hou J, Wang D, Zhang R, Wang H: Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and mechanisms of action. Clin Cancer Res. 2008, 14: 5519-5530. 10.1158/1078-0432.CCR-08-0197.PubMed
104.
Lu JJ, Meng LH, Cai YJ, Chen Q, Tong LJ, Lin LP, Ding J: Dihydroartemisinin induces apoptosis in HL-60 leukemia cells dependent of iron and p38 mitogen-activated protein kinase activation but independent of reactive oxygen species. Cancer Biol Ther. 2008, 7: 1017-1023. 10.4161/cbt.7.7.6035.PubMed
105.
Efferth T, Sauerbrey A, Olbrich A, Gebhart E, Rauch P, Weber HO, Hengstler JG, Halatsch ME, Volm M, Tew KD, Ross DD, Funk JO: Molecular modes of action of artesunate in tumor cell lines. Mol Pharmacol. 2003, 64: 382-394. 10.1124/mol.64.2.382.PubMed
106.
Lu JJ, Meng LH, Shankavaram UT, Zhu CH, Tong LJ, Chen G, Lin LP, Weinstein JN, Ding J: Dihydroartemisinin accelerates c-MYC oncoprotein degradation and induces apoptosis in c-MYC-overexpressing tumor cells. Biochem Pharmacol. 2010, 80: 22-30. 10.1016/j.bcp.2010.02.016.PubMed
107.
Chen H, Sun B, Pan S, Jiang H, Sun X: Dihydroartemisinin inhibits growth of pancreatic cancer cells in vitro and in vivo. Anticancer Drugs. 2009, 20: 131-140. 10.1097/CAD.0b013e3283212ade.PubMed
108.
Li LN, Zhang HD, Yuan SJ, Tian ZY, Wang L, Sun ZX: Artesunate attenuates the growth of human colorectal carcinoma and inhibits hyperactive Wnt/beta-catenin pathway. Int J Cancer. 2007, 121: 1360-1365. 10.1002/ijc.22804.PubMed
109.
Du JH, Zhang HD, Ma ZJ, Ji KM: Artesunate induces oncosis-like cell death in vitro and has antitumor activity against pancreatic cancer xenografts in vivo. Cancer Chemother Pharmacol. 2010, 65: 895-902. 10.1007/s00280-009-1095-5.PubMedCentralPubMed
110.
Mercer AE, Copple IM, Maggs JL, O'Neill PM, Park BK: The role of heme and the mitochondrion in the chemical and molecular mechanisms of mammalian cell death induced by the artemisinin antimalarials. J Biol Chem. 2011, 286: 987-996. 10.1074/jbc.M110.144188.PubMedCentralPubMed
111.
Zhang S, Chen H, Gerhard GS: Heme synthesis increases artemisinin -induced radical formation and cytotoxicity that can be suppressed by superoxide scavengers. Chem Biol Interact. 2010, 186: 30-35. 10.1016/j.cbi.2010.03.021.PubMed
112.
Zhang S, Gerhard GS: Heme mediates cytotoxicity from artemisinin and serves as a general anti-proliferation target. PLoS ONE. 2009, 4: e7472-10.1371/journal.pone.0007472.PubMedCentralPubMed
113.
Efferth T, Benakis A, Romero MR, Tomicic M, Rauh R, Steinbach D, Hafer R, Stamminger T, Oesch F, Kaina B, Marschall M: Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron. Free Radic Biol Med. 2004, 37: 998-1009. 10.1016/j.freeradbiomed.2004.06.023.PubMed
114.
Kelter G, Steinbach D, Konkimalla VB, Tahara T, Taketani S, Fiebig HH, Efferth T: Role of transferrin receptor and the ABC transporters ABCB6 and ABCB7 for resistance and differentiation of tumor cells towards artesunate. PLoS ONE. 2007, 2: e798-10.1371/journal.pone.0000798.PubMedCentralPubMed
115.
Lu JJ, Chen SM, Zhang XW, Ding J, Meng LH: The anti-cancer activity of dihydroartemisinin is associated with induction of iron-dependent endoplasmic reticulum stress in colorectal carcinoma HCT116 cells. Invest New Drugs. 2010,
116.
Stockwin LH, Han B, Yu SX, Hollingshead MG, ElSohly MA, Gul W, Slade D, Galal AM, Newton DL, Bumke MA: Artemisinin dimer anticancer activity correlates with heme-catalyzed reactive oxygen species generation and endoplasmic reticulum stress induction. Int J Cancer. 2009, 125: 1266-1275. 10.1002/ijc.24496.PubMedCentralPubMed
117.
Jiao Y, Ge CM, Meng QH, Cao JP, Tong J, Fan SJ: Dihydroartemisinin is an inhibitor of ovarian cancer cell growth. Acta pharmacol Sin. 2007, 28: 1045-1056. 10.1111/j.1745-7254.2007.00612.x.PubMed
118.
Handrick R, Ontikatze T, Bauer KD, Freier F, Rubel A, Durig J, Belka C, Jendrossek V: Dihydroartemisinin induces apoptosis by a Bak-dependent intrinsic pathway. Mol Cancer Ther. 2010, 9: 2497-2510. 10.1158/1535-7163.MCT-10-0051.PubMed
119.
Chen T, Li M, Zhang R, Wang H: Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cells to carboplatin therapy. J Cell Mol Med. 2009, 13: 1358-1370. 10.1111/j.1582-4934.2008.00360.x.PubMedCentralPubMed
120.
He Q, Shi J, Shen XL, An J, Sun H, Wang L, Hu YJ, Sun Q, Fu LC, Sheikh MS, Huang Y: Dihydroartemisinin upregulates death receptor 5 expression and cooperates with TRAIL to induce apoptosis in human prostate cancer cells. Cancer Biol Ther. 2010, 9: 819-824. 10.4161/cbt.9.10.11552.PubMed
121.
Zhou HJ, Wang WQ, Wu GD, Lee J, Li A: Artesunate inhibits angiogenesis and downregulates vascular endothelial growth factor expression in chronic myeloid leukemia K562 cells. Vascul Pharmacol. 2007, 47: 131-138. 10.1016/j.vph.2007.05.002.PubMed
122.
Chen HH, Zhou HJ, Wang WQ, Wu GD: Antimalarial dihydroartemisinin also inhibits angiogenesis. Cancer Chemother Pharmacol. 2004, 53: 423-432. 10.1007/s00280-003-0751-4.PubMed
123.
Anfosso L, Efferth T, Albini A, Pfeffer U: Microarray expression profiles of angiogenesis-related genes predict tumor cell response to artemisinins. Pharmacogenomics J. 2006, 6: 269-278.PubMed
124.
Lee J, Zhou HJ, Wu XH: Dihydroartemisinin downregulates vascular endothelial growth factor expression and induces apoptosis in chronic myeloid leukemia K562 cells. Cancer Chemother Pharmacol. 2006, 57: 213-220. 10.1007/s00280-005-0002-y.PubMed
125.
Buommino E, Baroni A, Canozo N, Petrazzuolo M, Nicoletti R, Vozza A, Tufano MA: Artemisinin reduces human melanoma cell migration by down-regulating alpha V beta 3 integrin and reducing metalloproteinase 2 production. Invest New Drugs. 2009, 27: 412-418. 10.1007/s10637-008-9188-2.PubMed
126.
Rasheed SA, Efferth T, Asangani IA, Allgayer H: First evidence that the antimalarial drug artesunate inhibits invasion and in vivo metastasis in lung cancer by targeting essential extracellular proteases. Int J Cancer. 2010, 127: 1475-1485. 10.1002/ijc.25315.PubMed
127.
Efferth T, Ramirez T, Gebhart E, Halatsch ME: Combination treatment of glioblastoma multiforme cell lines with the anti-malarial artesunate and the epidermal growth factor receptor tyrosine kinase inhibitor OSI-774. Biochem Pharmacol. 2004, 67: 1689-1700. 10.1016/j.bcp.2003.12.035.PubMed
128.
Li QQ, Wang GD, Huang FR, Banda M, Reed E: Antineoplastic effect of beta-elemene on prostate cancer cells and other types of solid tumour cells. J Pharm Pharmacol. 2010, 62: 1018-1027.PubMed
129.
Wang G, Li X, Huang F, Zhao J, Ding H, Cunningham C, Coad JE, Flynn DC, Reed E, Li QQ: Antitumor effect of beta-elemene in non-small-cell lung cancer cells is mediated via induction of cell cycle arrest and apoptotic cell death. Cell Mol Life Sci. 2005, 62: 881-893. 10.1007/s00018-005-5017-3.PubMed
130.
Li X, Wang G, Zhao J, Ding H, Cunningham C, Chen F, Flynn DC, Reed E, Li QQ: Antiproliferative effect of beta-elemene in chemoresistant ovarian carcinoma cells is mediated through arrest of the cell cycle at the G2-M phase. Cell Mol Life Sci. 2005, 62: 894-904. 10.1007/s00018-005-5027-1.PubMed
131.
Zhao J, Li QQ, Zou B, Wang G, Li X, Kim JE, Cuff CF, Huang L, Reed E, Gardner K: In vitro combination characterization of the new anticancer plant drug beta-elemene with taxanes against human lung carcinoma. Inter J Oncol. 2007, 31: 241-252.
132.
Yao YQ, Ding X, Jia YC, Huang CX, Wang YZ, Xu YH: Anti-tumor effect of beta-elemene in glioblastoma cells depends on p38 MAPK activation. Cancer Lett. 2008, 264: 127-134. 10.1016/j.canlet.2008.01.049.PubMed
133.
Tao L, Zhou L, Zheng L, Yao M: Elemene displays anti-cancer ability on laryngeal cancer cells in vitro and in vivo. Cancer Chemother Pharmacol. 2006, 58: 24-34. 10.1007/s00280-005-0137-x.PubMed
134.
Wu XS, Xie T, Lin J, Fan HZ, Huang-Fu HJ, Ni LF, Yan HF: An investigation of the ability of elemene to pass through the blood-brain barrier and its effect on brain carcinomas. J Pharm Pharmacol. 2009, 61: 1653-1656.PubMed
135.
Liao WL, Du Z, Zhang T, Guo XL, Wen YT, Yu Q, Luo AQ, Li WM: Qualitative and quantitative evaluation of Rabdosia Rubescens (Hemls.) Hara of different areas. Central South Pharmacy. 2010, 12: 912-915.
136.
Liu JJ, Huang RW, Lin DJ, Wu XY, Peng J, Pan XL, Lin Q, Hou M, Zhang MH, Chen F: Antiproliferation effects of oridonin on HPB-ALL cells and its mechanisms of action. Am J Hematol. 2006, 81: 86-94. 10.1002/ajh.20524.PubMed
137.
Liu JJ, Huang RW, Lin DJ, Peng J, Wu XY, Pan XL, Li MQ, Lin Q: Anti-proliferative effects of oridonin on SPC-A-1 cells and its mechanism of action. J Int Med Res. 2004, 32: 617-625.PubMed
138.
Cui Q, Tashiro S, Onodera S, Ikejima T: Augmentation of oridonin-induced apoptosis observed with reduced autophagy. J Pharmacol Sci. 2006, 101: 230-239. 10.1254/jphs.FPJ06003X.PubMed
139.
Wu JN, Huang J, Yang J, Tashiro S, Onodera S, Ikejima T: Caspase inhibition augmented oridonin-induced cell death in murine fibrosarcoma l929 by enhancing reactive oxygen species generation. J Pharmacol Sci. 2008, 108: 32-39. 10.1254/jphs.FP0072079.PubMed
140.
Kang N, Zhang JH, Qiu F, Tashiro S, Onodera S, Ikejima T: Inhibition of EGFR signaling augments oridonin-induced apoptosis in human laryngeal cancer cells via enhancing oxidative stress coincident with activation of both the intrinsic and extrinsic apoptotic pathways. Cancer Lett. 2010, 294: 147-158. 10.1016/j.canlet.2010.01.032.PubMed
141.
Zhang Y, Wu Y, Tashiro S, Onodera S, Ikejima T: Involvement of PKC signal pathways in oridonin-induced autophagy in HeLa cells: a protective mechanism against apoptosis. Biochem Biophys Res Commun. 2009, 378: 273-278. 10.1016/j.bbrc.2008.11.038.PubMed
142.
Wang H, Ye Y, Pan SY, Zhu GY, Li YW, Fong DW, Yu ZL: Proteomic identification of proteins involved in the anticancer activities of oridonin in HepG2 cells. Phytomedicine. 2011, 18: 163-169. 10.1016/j.phymed.2010.06.011.PubMed
143.
Kang N, Zhang JH, Qiu F, Chen S, Tashiro S, Onodera S, Ikejima T: Induction of G(2)/M phase arrest and apoptosis by oridonin in human laryngeal carcinoma cells. J Nat Prod. 2010, 73: 1058-1063. 10.1021/np9008199.PubMed
144.
Liu YQ, Mu ZQ, You S, Tashiro S, Onodera S, Ikejima T: Fas/FasL signaling allows extracelluar-signal regulated kinase to regulate cytochrome c release in oridonin-induced apoptotic U937 cells. Biol Pharm Bull. 2006, 29: 1873-1879. 10.1248/bpb.29.1873.PubMed
145.
Li D, Wu LJ, Tashiro S, Onodera S, Ikejima T: Oridonin induces human epidermoid carcinoma A431 cell apoptosis through tyrosine kinase and mitochondrial pathway. J Asian Nat Prod Res. 2008, 10: 77-87. 10.1080/10286020701273866.PubMed
146.
Zhang CL, Wu LJ, Tashiro S, Onodera S, Ikejima T: Oridonin induced A375-S2 cell apoptosis via bax-regulated caspase pathway activation, dependent on the cytochrome c/caspase-9 apoptosome. J Asian Nat Prod Res. 2004, 6: 127-138. 10.1080/1028602031000147375.PubMed
147.
Zhang CL, Wu LJ, Zuo HJ, Tashiro S, Onodera S, Ikejima T: Cytochrome c release from oridonin-treated apoptotic A375-S2 cells is dependent on p53 and extracellular signal-regulated kinase activation. J Pharmacol Sci. 2004, 96: 155-163. 10.1254/jphs.FPJ04008X.PubMed
148.
Liu J, Huang R, Lin D, Wu X, Peng J, Lin Q, Pan X, Zhang M, Hou M, Chen F: Apoptotic effect of oridonin on NB4 cells and its mechanism. Leuk Lymphoma. 2005, 46: 593-597. 10.1080/10428190400019800.PubMed
149.
Zhang CL, Wu LJ, Tashiro S, Onodera S, Ikejima T: Oridonin induces a caspase-independent but mitochondria- and MAPK-dependent cell death in the murine fibrosarcoma cell line L929. Biol Pharm Bull. 2004, 27: 1527-1531. 10.1248/bpb.27.1527.PubMed
150.
Cui Q, Yu JH, Wu JN, Tashiro S, Onodera S, Minami M, Ikejima T: P53-mediated cell cycle arrest and apoptosis through a caspase-3- independent, but caspase-9-dependent pathway in oridonin-treated MCF-7 human breast cancer cells. Acta Pharmacol Sin. 2007, 28: 1057-1066. 10.1111/j.1745-7254.2007.00588.x.PubMed
151.
Cheng Y, Qiu F, Ikejima T: Molecular mechanisms of oridonin-induced apoptosis and autophagy in murine fibrosarcoma L929 cells. Autophagy. 2009, 5: 430-431. 10.4161/auto.5.3.7896.PubMed
152.
Cheng Y, Qiu F, Ye YC, Tashiro S, Onodera S, Ikejima T: Oridonin induces G2/M arrest and apoptosis via activating ERK-p53 apoptotic pathway and inhibiting PTK-Ras-Raf-JNK survival pathway in murine fibrosarcoma L929 cells. Arch Biochem Biophys. 2009, 490: 70-75. 10.1016/j.abb.2009.08.011.PubMed
153.
Wang HJ, Li D, Yang FY, Tashiro S, Onodera S, Ikejima T: Oridonin induces human melanoma A375-S2 cell death partially through inhibiting insulin-like growth factor 1 receptor signaling. J Asian Nat Prod Res. 2008, 10: 787-798.PubMed
154.
Li D, Wu LJ, Tashiro S, Onodera S, Ikejima T: Oridonin inhibited the tyrosine kinase activity and induced apoptosis in human epidermoid carcinoma A431 cells. Biol Pharm Bull. 2007, 30: 254-260. 10.1248/bpb.30.254.PubMed
155.
Ikezoe T, Yang Y, Bandobashi K, Saito T, Takemoto S, Machida H, Togitani K, Koeffler HP, Taguchi H: Oridonin, a diterpenoid purified from Rabdosia rubescens, inhibits the proliferation of cells from lymphoid malignancies in association with blockade of the NF-kappa B signal pathways. Mol Cancer Ther. 2005, 4: 578-586. 10.1158/1535-7163.MCT-04-0277.PubMed
156.
Gao FH, Hu XH, Li W, Liu H, Zhang YJ, Guo ZY, Xu MH, Wang ST, Jiang B, Liu F, Zhao YZ, Fang Y, Chen FY, Wu YL: Oridonin induces apoptosis and senescence in colorectal cancer cells by increasing histone hyperacetylation and regulation of p16, p21, p27 and c-myc. BMC Cancer. 2010, 10: 610-10.1186/1471-2407-10-610.PubMedCentralPubMed
157.
Cui Q, Tashiro S, Onodera S, Minami M, Ikejima T: Autophagy preceded apoptosis in oridonin-treated human breast cancer MCF-7 cells. Biol Pharm Bull. 2007, 30: 859-864. 10.1248/bpb.30.859.PubMed
158.
Li D, Cui Q, Chen SG, Wu LJ, Tashiro S, Onodera S, Ikejima T: Inactivation of ras and changes of mitochondrial membrane potential contribute to oridonin-induced autophagy in a431 cells. J Pharmacol Sci. 2007, 105: 22-33. 10.1254/jphs.FPJ06022X.PubMed
159.
Zhang Y, Wu Y, Wu D, Tashiro S, Onodera S, Ikejima T: NF-kappab facilitates oridonin-induced apoptosis and autophagy in HT1080 cells through a p53-mediated pathway. Arch Biochem Biophys. 2009, 489: 25-33. 10.1016/j.abb.2009.07.017.PubMed
160.
Cheng Y, Qiu F, Ye YC, Guo ZM, Tashiro S, Onodera S, Ikejima T: Autophagy inhibits reactive oxygen species-mediated apoptosis via activating p38-nuclear factor-kappa B survival pathways in oridonin-treated murine fibrosarcoma L929 cells. FEBS J. 2009, 276: 1291-1306. 10.1111/j.1742-4658.2008.06864.x.PubMed
161.
Wang MY, Lin C, Zhang TM: Effects of oridonin on DNA, RNA and protein syntheses of leukemia L 1210 cells studied by autoradiography. Zhongguo Yao Li Xue Bao. 1987, 8: 164-165.PubMed
162.
Liu JJ, Wu XY, Peng J, Pan XL, Lu HL: Antiproliferation effects of oridonin on HL-60 cells. Ann Hematol. 2004, 83: 691-695. 10.1007/s00277-004-0919-y.PubMed
163.
Lou H, Zhang X, Gao L, Feng F, Wang J, Wei X, Yu Z, Zhang D, Zhang Q: In vitro and in vivo antitumor activity of oridonin nanosuspension. Int J Pharm. 2009, 379: 181-186. 10.1016/j.ijpharm.2009.06.022.PubMed
164.
Zhou GB, Kang H, Wang L, Gao L, Liu P, Xie J, Zhang FX, Weng XQ, Shen ZX, Chen J, Gu LJ, Yan M, Zhang DE, Chen SJ, Wang ZY, Chen Z: Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo. Blood. 2007, 109: 3441-3450. 10.1182/blood-2006-06-032250.PubMedCentralPubMed
165.
He MF, Liu L, Ge W, Shaw PC, Jiang R, Wu LW, But PP: Antiangiogenic activity of Tripterygium wilfordii and its terpenoids. J Ethnopharmacol. 2009, 121: 61-68. 10.1016/j.jep.2008.09.033.PubMed
166.
Li H, Takai N, Yuge A, Furukawa Y, Tsuno A, Tsukamoto Y, Kong S, Moriyama M, Narahara H: Novel target genes responsive to the anti-growth activity of triptolide in endometrial and ovarian cancer cells. Cancer Lett. 2010, 297: 198-206. 10.1016/j.canlet.2010.05.012.PubMed
167.
Zhao F, Chen Y, Zeng L, Li R, Zeng R, Wen L, Liu Y, Zhang C: Role of triptolide in cell proliferation, cell cycle arrest, apoptosis and histone methylation in multiple myeloma U266 cells. Eur J Pharmacol. 2010, 646: 1-11. 10.1016/j.ejphar.2010.05.034.PubMed
168.
Zhou GS, Hu Z, Fang HT, Zhang FX, Pan XF, Chen XQ, Hu AM, Xu L, Zhou GB: Biologic activity of triptolide in t(8;21) acute myeloid leukemia cells. Leuk Res. 2011, 35: 214-218. 10.1016/j.leukres.2010.07.013.PubMed
169.
Zhu W, Hu H, Qiu P, Yan G: Triptolide induces apoptosis in human anaplastic thyroid carcinoma cells by a p53-independent but NF-kappaB- related mechanism. Oncol Rep. 2009, 22: 1397-1401.PubMed
170.
Zhou GX, Ding XL, Huang JF, Zhang H, Wu SB: Suppression of 5-lipoxygenase gene is involved in triptolide-induced apoptosis in pancreatic tumor cell lines. Biochim Biophys Acta. 2007, 1770: 1021-1027.PubMed
171.
Clawson KA, Borja-Cacho D, Antonoff MB, Saluja AK, Vickers SM: Triptolide and TRAIL combination enhances apoptosis in cholangiocarcinoma. J Surg Res. 2010, 163: 244-249. 10.1016/j.jss.2010.03.067.PubMedCentralPubMed
172.
Carter BZ, Mak DH, Schober WD, McQueen T, Harris D, Estrov Z, Evans RL, Andreeff M: Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells. Blood. 2006, 108: 630-637. 10.1182/blood-2005-09-3898.PubMedCentralPubMed
173.
Wan CK, Wang C, Cheung HY, Yang M, Fong WF: Triptolide induces Bcl-2 cleavage and mitochondria dependent apoptosis in p53-deficient HL-60 cells. Cancer Lett. 2006, 241: 31-41. 10.1016/j.canlet.2005.10.001.PubMed
174.
Johnson SM, Wang X, Mark Evers B: Triptolide Inhibits Proliferation and Migration of Colon Cancer Cells by Inhibition of Cell Cycle Regulators and Cytokine Receptors. J Surg Res. 2011, 168: 197-205. 10.1016/j.jss.2009.07.002.PubMedCentralPubMed
175.
Chang HJ, Kim MH, Baek MK, Park JS, Chung IJ, Shin BA, Ahn BW, Jung YD: Triptolide inhibits tumor promoter-induced uPAR expression via blocking NF-kappaB signaling in human gastric AGS cells. Anticancer Res. 2007, 27: 3411-3417.PubMed
176.
Zhu W, He S, Li Y, Qiu P, Shu M, Ou Y, Zhou Y, Leng T, Xie J, Zheng X, Xu D, Su X, Yan G: Anti-angiogenic activity of triptolide in anaplastic thyroid carcinoma is mediated by targeting vascular endothelial and tumor cells. Vascul Pharmacol. 2010, 52: 46-54. 10.1016/j.vph.2009.10.006.PubMed
177.
Liang M, Fu J: Triptolide inhibits interferon-gamma-induced programmed death-1-ligand 1 surface expression in breast cancer cells. Cancer Lett. 2008, 270: 337-341. 10.1016/j.canlet.2008.05.025.PubMed
178.
Yang S, Chen J, Guo Z, Xu XM, Wang L, Pei XF, Yang J, Underhill CB, Zhang L: Triptolide inhibits the growth and metastasis of solid tumors. Mol Cancer Ther. 2003, 2: 65-72.PubMed
179.
Zhang C, Cui GH, Liu F, Wu QL, Chen Y: Inhibitory effect of triptolide on lymph node metastasis in patients with non-Hodgkin lymphoma by regulating SDF-1/CXCR4 axis in vitro. Acta pharmacologica Sinica. 2006, 27: 1438-1446. 10.1111/j.1745-7254.2006.00415.x.PubMed
180.
Tang XY, Zhu YQ, Tao WH, Wei B, Lin XL: Synergistic effect of triptolide combined with 5-fluorouracil on colon carcinoma. Postgrad Med J. 2007, 83: 338-343. 10.1136/pgmj.2006.055426.PubMedCentralPubMed
181.
Yang SW, Wang W, Xie XY, Zhu WP, Li FQ: In vitro synergistic cytotoxic effect of triptolide combined with hydroxycamptothecin on pancreatic cancer cells. Am J Chin Med. 2011, 39: 121-134. 10.1142/S0192415X11008695.PubMed
182.
Pigneux A, Mahon FX, Uhalde M, Jeanneteau M, Lacombe F, Milpied N, Reiffers J, Belloc F: Triptolide cooperates with chemotherapy to induce apoptosis in acute myeloid leukemia cells. Exp Hematol. 2008, 36: 1648-1659. 10.1016/j.exphem.2008.08.002.PubMed
183.
Carter BZ, Mak DH, Schober WD, Dietrich MF, Pinilla C, Vassilev LT, Reed JC, Andreeff M: Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5. Blood. 2008, 111: 3742-3750. 10.1182/blood-2007-05-091504.PubMedCentralPubMed
184.
Wang W, Yang S, Su Y, Xiao Z, Wang C, Li X, Lin L, Fenton BM, Paoni SF, Ding I, Keng P, Okunieff P, Zhang L: Enhanced antitumor effect of combined triptolide and ionizing radiation. Clin Cancer Res. 2007, 13: 4891-4899. 10.1158/1078-0432.CCR-07-0416.PubMed
185.
Wang X, Li L, Wang B, Xiang J: Effects of ursolic acid on the proliferation and apoptosis of human ovarian cancer cells. J Huazhong Uni Sci Technol Med Sci. 2009, 29: 761-764. 10.1007/s11596-009-0618-y.
186.
Yang L, Liu X, Lu Z, Yuet-Wa Chan J, Zhou L, Fung KP, Wu P, Wu S: Ursolic acid induces doxorubicin-resistant HepG2 cell death via the release of apoptosis-inducing factor. Cancer Lett. 2010, 298: 128-138. 10.1016/j.canlet.2010.06.010.PubMed
187.
De Angel RE, Smith SM, Glickman RD, Perkins SN, Hursting SD: Antitumor effects of ursolic acid in a mouse model of postmenopausal breast cancer. Nutr Cancer. 2010, 62: 1074-1086. 10.1080/01635581.2010.492092.PubMed
188.
Meng Y, Song Y, Yan Z, Xia Y: Synthesis and in vitro cytotoxicity of novel ursolic acid derivatives. Molecules (Basel, Switzerland). 2010, 15: 4033-4040.
189.
Kwon SH, Park HY, Kim JY, Jeong IY, Lee MK, Seo KI: Apoptotic action of ursolic acid isolated from Corni fructus in RC-58T/h/SA#4 primary human prostate cancer cells. Bioorg Med Chem Lett. 2010, 20: 6435-6438. 10.1016/j.bmcl.2010.09.073.PubMed
190.
Zhang Y, Kong C, Zeng Y, Wang L, Li Z, Wang H, Xu C, Sun Y: Ursolic acid induces PC-3 cell apoptosis via activation of JNK and inhibition of Akt pathways in vitro. Mol Carcinog. 2010, 49: 374-385.PubMed
191.
Yeh CT, Wu CH, Yen GC: Ursolic acid, a naturally occurring triterpenoid, suppresses migration and invasion of human breast cancer cells by modulating c-Jun N-terminal kinase, Akt and mammalian target of rapamycin signaling. Mol Nutr Food Res. 2010, 54: 1285-1295. 10.1002/mnfr.200900414.PubMed
192.
Huang HC, Huang CY, Lin-Shiau SY, Lin JK: Ursolic acid inhibits IL-1beta or TNF-alpha-induced C6 glioma invasion through suppressing the association ZIP/p62 with PKC-zeta and downregulating the MMP-9 expression. Mol Carcinog. 2009, 48: 517-531. 10.1002/mc.20490.PubMed
193.
Kanjoormana M, Kuttan G: Antiangiogenic activity of ursolic acid. Integr Cancer Ther. 2010, 9: 224-235. 10.1177/1534735410367647.PubMed
194.
Lin CC, Huang CY, Mong MC, Chan CY, Yin MC: Antiangiogenic Potential of Three Triterpenic Acids in Human Liver Cancer Cells. J Agric Food Chem. 2010, 755-762.
195.
Wu Z, Wu L, Li L, Tashiro S, Onodera S, Ikejima T: p53-mediated cell cycle arrest and apoptosis induced by shikonin via a caspase-9-dependent mechanism in human malignant melanoma A375-S2 cells. J Pharmacol Sci. 2004, 94: 166-176. 10.1254/jphs.94.166.PubMed
196.
Wu Z, Wu LJ, Li LH, Tashiro S, Onodera S, Ikejima T: Shikonin regulates HeLa cell death via caspase-3 activation and blockage of DNA synthesis. J Asian Nat Prod Res. 2004, 6: 155-166. 10.1080/1028602032000169622.PubMed
197.
Yeh CC, Kuo HM, Li TM, Lin JP, Yu FS, Lu HF, Chung JG, Yang JS: Shikonin-induced apoptosis involves caspase-3 activity in a human bladder cancer cell line (T24). In Vivo. 2007, 21: 1011-1019.PubMed
198.
Yoon Y, Kim YO, Lim NY, Jeon WK, Sung HJ: Shikonin, an ingredient of Lithospermum erythrorhizon induced apoptosis in HL60 human premyelocytic leukemia cell line. Planta Med. 1999, 65: 532-535. 10.1055/s-1999-14010.PubMed
199.
Han W, Li L, Qiu S, Lu Q, Pan Q, Gu Y, Luo J, Hu X: Shikonin circumvents cancer drug resistance by induction of a necroptotic death. Mol Cancer Ther. 2007, 6: 1641-1649. 10.1158/1535-7163.MCT-06-0511.PubMed
200.
Han W, Xie J, Li L, Liu Z, Hu X: Necrostatin-1 reverts shikonin-induced necroptosis to apoptosis. Apoptosis. 2009, 14: 674-686. 10.1007/s10495-009-0334-x.PubMed
201.
Min R, Tong J, Wenjun Y, Wenhu D, Xiaojian Z, Jiacai H, Jian Z, Wantao C, Chenping Z: Growth inhibition and induction of apoptosis in human oral squamous cell carcinoma Tca-8113 cell lines by Shikonin was partly through the inactivation of NF-kappaB pathway. Phytother Res. 2008, 22: 407-415. 10.1002/ptr.2340.PubMed
202.
Nie YK, Zhu LS, Yu HM: Shikonin inhibits the proliferation and induces the apoptosis of human HepG2 cells. Can J Physiol Pharm. 2010, 88: 1138-1146. 10.1139/Y10-085.
203.
Chang IC, Huang YJ, Chiang TI, Yeh CW, Hsu LS: Shikonin Induces Apoptosis through Reactive Oxygen Species/Extracellular Signal- Regulated Kinase Pathway in Osteosarcoma Cells. Biol Pharm Bull. 2010, 33: 816-824. 10.1248/bpb.33.816.PubMed
204.
Mao X, Yu CR, Li WH, Li WX: Induction of apoptosis by shikonin through a ROS/JNK-mediated process in Bcr/Abl-positive chronic myelogenous leukemia (CML) cells. Cell Res. 2008, 18: 879-888. 10.1038/cr.2008.86.PubMed
205.
Yang H, Zhou P, Huang H, Chen D, Ma N, Cui QC, Shen S, Dong W, Zhang X, Lian W, Wang X, Dou QP, Liu J: Shikonin exerts antitumor activity via proteasome inhibition and cell death induction in vitro and in vivo. Int J Cancer. 2009, 124: 2450-2459. 10.1002/ijc.24195.PubMedCentralPubMed
206.
Yang F, Chen Y, Duan W, Zhang C, Zhu H, Ding J: SH-7, a new synthesized shikonin derivative, exerting its potent antitumor activities as a topoisomerase inhibitor. Int J Cancer. 2006, 119: 1184-1193. 10.1002/ijc.21943.PubMed
207.
Yao Y, Zhou Q: A novel antiestrogen agent Shikonin inhibits estrogen- dependent gene transcription in human breast cancer cells. Breast Cancer Res Tr. 2010, 121: 233-240. 10.1007/s10549-009-0547-2.
208.
Yao YA, Brodie AMH, Davidson NE, Kensler TW, Zhou Q: Inhibition of estrogen signaling activates the NRF2 pathway in breast cancer. Breast Cancer Res Tr. 2010, 124: 585-591. 10.1007/s10549-010-1023-8.
209.
Min R, Zun Z, Min Y, Wenhu D, Wenjun Y, Chenping Z: Shikonin inhibits tumor invasion via down-regulation of NF-kappaB-mediated MMP-9 expression in human ACC-M cells. Oral Dis. 2011, 17: 362-369. 10.1111/j.1601-0825.2010.01758.x.PubMed
210.
Wang L, Li D, Bao C, You J, Wang Z, Shi Y, Zhang H: Ultrasonic extraction and separation of anthraquinones from Rheum palmatum L. Ultrason Sonochem. 2008, 15: 738-746. 10.1016/j.ultsonch.2007.12.008.PubMed
211.
Srinivas G, Babykutty S, Sathiadevan PP, Srinivas P: Molecular mechanism of emodin action: transition from laxative ingredient to an antitumor agent. Med Res Rev. 2007, 27: 591-608. 10.1002/med.20095.PubMed
212.
Chun-Guang W, Jun-Qing Y, Bei-Zhong L, Dan-Ting J, Chong W, Liang Z, Dan Z, Yan W: Anti-tumor activity of emodin against human chronic myelocytic leukemia K562 cell lines in vitro and in vivo. Eur J Pharmacol. 2010, 627: 33-41. 10.1016/j.ejphar.2009.10.035.PubMed
213.
Muto A, Hori M, Sasaki Y, Saitoh A, Yasuda I, Maekawa T, Uchida T, Asakura K, Nakazato T, Kaneda T, Kizaki M, Ikeda Y, Yoshida T: Emodin has a cytotoxic activity against human multiple myeloma as a Janus-activated kinase 2 inhibitor. Mol Cancer Ther. 2007, 6: 987-994.PubMed
214.
Su YT, Chang HL, Shyue SK, Hsu SL: Emodin induces apoptosis in human lung adenocarcinoma cells through a reactive oxygen species-dependent mitochondrial signaling pathway. Biochem Pharmacol. 2005, 70: 229-241. 10.1016/j.bcp.2005.04.026.PubMed
215.
Cha TL, Qiu L, Chen CT, Wen Y, Hung MC: Emodin down-regulates androgen receptor and inhibits prostate cancer cell growth. Cancer Res. 2005, 65: 2287-2295. 10.1158/0008-5472.CAN-04-3250.PubMed
216.
Li Y, Luan Y, Qi X, Li M, Gong L, Xue X, Wu X, Wu Y, Chen M, Xing G, Yao J, Ren Jl: Emodin triggers DNA double-strand breaks by stabilizing topoisomerase II-DNA cleavage complexes and by inhibiting ATP hydrolysis of topoisomerase II. Toxicol Sci. 2010, 118: 435-443. 10.1093/toxsci/kfq282.PubMed
217.
Ko JC, Su YJ, Lin ST, Jhan JY, Ciou SC, Cheng CM, Lin YW: Suppression of ERCC1 and Rad51 expression through ERK1/2 inactivation is essential in emodin-mediated cytotoxicity in human non-small cell lung cancer cells. Biochem Pharmacol. 2010, 79: 655-664. 10.1016/j.bcp.2009.09.024.PubMed
218.
Kwak HJ, Park MJ, Park CM, Moon SI, Yoo DH, Lee HC, Lee SH, Kim MS, Lee HW, Shin WS, Park IC, Rhee CH, Hong SI: Emodin inhibits vascular endothelial growth factor-A-induced angiogenesis by blocking receptor-2 (KDR/Flk-1) phosphorylation. Int J Cancer. 2006, 118: 2711-2720. 10.1002/ijc.21641.PubMed
219.
Huang Q, Shen HM, Ong CN: Emodin inhibits tumor cell migration through suppression of the phosphatidylinositol 3-kinase-Cdc42/Rac1 pathway. Cell Mol Life Sci. 2005, 62: 1167-1175. 10.1007/s00018-005-5050-2.PubMed
220.
Huang Q, Shen HM, Shui G, Wenk MR, Ong CN: Emodin inhibits tumor cell adhesion through disruption of the membrane lipid Raft-associated integrin signaling pathway. Cancer Res. 2006, 66: 5807-5815. 10.1158/0008-5472.CAN-06-0077.PubMed
221.
Wang XJ, Yang J, Cang H, Zou YQ, Yi J: Gene expression alteration during redox-dependent enhancement of arsenic cytotoxicity by emodin in HeLa cells. Cell Res. 2005, 15: 511-522. 10.1038/sj.cr.7290321.PubMed
222.
Cai J, Niu X, Chen Y, Hu Q, Shi G, Wu H, Wang J, Yi J: Emodin-induced generation of reactive oxygen species inhibits RhoA activation to sensitize gastric carcinoma cells to anoikis. Neoplasia. 2008, 10: 41-51. 10.1593/neo.07754.PubMedCentralPubMed
223.
Huang XZ, Wang J, Huang C, Chen YY, Shi GY, Hu QS, Yi J: Emodin enhances cytotoxicity of chemotherapeutic drugs in prostate cancer cells: the mechanisms involve ROS-mediated suppression of multidrug resistance and hypoxia inducible factor-1. Cancer Biol Ther. 2008, 7: 468-475. 10.4161/cbt.7.3.5457.PubMed
224.
Wang W, Sun YP, Huang XZ, He M, Chen YY, Shi GY, Li H, Yi J, Wang J: Emodin enhances sensitivity of gallbladder cancer cells to platinum drugs via glutathion depletion and MRP1 downregulation. Biochem Pharmacol. 2010, 79: 1134-1140. 10.1016/j.bcp.2009.12.006.PubMed
225.
Chen RS, Jhan JY, Su YJ, Lee WT, Cheng CM, Ciou SC, Lin ST, Chuang SM, Ko JC, Lin YW: Emodin enhances gefitinib-induced cytotoxicity via Rad51 downregulation and ERK1/2 inactivation. Exp Cell Res. 2009, 315: 2658-2672. 10.1016/j.yexcr.2009.06.002.PubMed
226.
Ko JC, Su YJ, Lin ST, Jhan JY, Ciou SC, Cheng CM, Chiu YF, Kuo YH, Tsai MS, Lin YW: Emodin enhances cisplatin-induced cytotoxicity via down- regulation of ERCC1 and inactivation of ERK1/2. Lung Cancer. 2010, 69: 155-164. 10.1016/j.lungcan.2009.10.013.PubMed
227.
Yue PY, Wong DY, Wu PK, Leung PY, Mak NK, Yeung HW, Liu L, Cai Z, Jiang ZH, Fan TP, Wong RN: The angiosuppressive effects of 20(R)- ginsenoside Rg3. Biochem Pharmacol. 2006, 72: 437-445. 10.1016/j.bcp.2006.04.034.PubMed
228.
Liu TG, Huang Y, Cui DD, Huang XB, Mao SH, Ji LL, Song HB, Yi C: Inhibitory effect of ginsenoside Rg3 combined with gemcitabine on angiogenesis and growth of lung cancer in mice. BMC Cancer. 2009, 9: 250-10.1186/1471-2407-9-250.PubMedCentralPubMed
229.
Kim SM, Lee SY, Yuk DY, Moon DC, Choi SS, Kim Y, Han SB, Oh KW, Hong JT: Inhibition of NF-kappaB by ginsenoside Rg3 enhances the susceptibility of colon cancer cells to docetaxel. Arch Pharm Res. 2009, 32: 755-765. 10.1007/s12272-009-1515-4.PubMed
230.
Kim SM, Lee SY, Cho JS, Son SM, Choi SS, Yun YP, Yoo HS, Yoon do Y, Oh KW, Han SB, Hong JT: Combination of ginsenoside Rg3 with docetaxel enhances the susceptibility of prostate cancer cells via inhibition of NF-kappaB. Eur J Pharmacol. 2010, 631: 1-9. 10.1016/j.ejphar.2009.12.018.PubMed
231.
Kim HS, Lee EH, Ko SR, Choi KJ, Park JH, Im DS: Effects of ginsenosides Rg3 and Rh2 on the proliferation of prostate cancer cells. Arch Pharm Res. 2004, 27: 429-435. 10.1007/BF02980085.PubMed
232.
He BC, Gao JL, Luo X, Luo J, Shen J, Wang L, Zhou Q, Wang YT, Luu HH, Haydon RC, Wang CZ, Du W, Yuan CS, He TC, Zhang BQ: Ginsenoside Rg3 inhibits colorectal tumor growth through the down-regulation of Wnt/ß-catenin signaling. Int J Oncol. 2011, 38: 437-445.PubMed
233.
Luo X, Wang CZ, Chen J, Song WX, Luo J, Tang N, He BC, Kang Q, Wang Y, Du W, He TC, Yuan CS: Characterization of gene expression regulated by American ginseng and ginsenoside Rg3 in human colorectal cancer cells. Int J Oncol. 2008, 32: 975-983.PubMedCentralPubMed
234.
Lee SY, Kim GT, Roh SH, Song JS, Kim HJ, Hong SS, Kwon SW, Park JH: Proteomic analysis of the anti-cancer effect of 20S-ginsenoside Rg3 in human colon cancer cell lines. Biosci Biotechnol Biochem. 2009, 73: 811-816. 10.1271/bbb.80637.PubMed
235.
Xu TM, Cui MH, Xin Y, Gu LP, Jiang X, Su MM, Wang DD, Wang WJ: Inhibitory effect of ginsenoside Rg3 on ovarian cancer metastasis. Chin Med J (Engl). 2008, 121: 1394-1397.
236.
Zhang Q, Kang X, Zhao W: Antiangiogenic effect of low-dose cyclophosphamide combined with ginsenoside Rg3 on Lewis lung carcinoma. Biochem Biophys Res Commun. 2006, 342: 824-828. 10.1016/j.bbrc.2006.02.044.PubMed
Metadata
Title
Anti-cancer natural products isolated from chinese medicinal herbs
Authors
Wen Tan
Jinjian Lu
Mingqing Huang
Yingbo Li
Meiwan Chen
Guosheng Wu
Jian Gong
Zhangfeng Zhong
Zengtao Xu
Yuanye Dang
Jiajie Guo
Xiuping Chen
Yitao Wang
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Chinese Medicine / Issue 1/2011
Electronic ISSN: 1749-8546
DOI
https://doi.org/10.1186/1749-8546-6-27

Other articles of this Issue 1/2011

Chinese Medicine 1/2011 Go to the issue

Review

Recent advances in nanoparticle formulation of oleanolic acid

Research

Myocardial post-conditioning with Danshen-Gegen decoction protects against isoproterenol-induced myocardial injury via a PKCε/mKATP-mediated pathway in rats

Commentary

Scope of claim coverage in patents of fufang Chinese herbal drugs: Substitution of ingredients

Review

Forensically informative nucleotide sequencing (FINS) for the authentication of Chinese medicinal materials

Research

Chinese herbal extracts of Rubia cordifolia and Dianthus superbus suppress IgE production and prevent peanut-induced anaphylaxis

Research

Gastrointestinal symptoms of infantile colic and their change after light needling of acupuncture: a case series study of 913 infants